Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors (Q60045844)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30573963 AND SRC:MED&resulttype=core&format=json

15 April 2020

title

Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30573963 AND SRC:MED&resulttype=core&format=json

15 April 2020

author name string

Pallavi Rane

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30573963 AND SRC:MED&resulttype=core&format=json

15 April 2020

Jeetvan Patel

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30573963 AND SRC:MED&resulttype=core&format=json

15 April 2020

Dionne M Hines

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30573963 AND SRC:MED&resulttype=core&format=json

15 April 2020

David J Harrison

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30573963 AND SRC:MED&resulttype=core&format=json

15 April 2020

Rolin L Wade

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30573963 AND SRC:MED&resulttype=core&format=json

15 April 2020

language of work or name

English

0 references

publication date

10 December 2018

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30573963 AND SRC:MED&resulttype=core&format=json

Vascular Health and Risk Management

15 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30573963 AND SRC:MED&resulttype=core&format=json

15 April 2020

volume

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30573963 AND SRC:MED&resulttype=core&format=json

15 April 2020

page(s)

409-418

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30573963 AND SRC:MED&resulttype=core&format=json

Creative Commons Attribution-NonCommercial 3.0 Unported

15 April 2020

copyright license

start time

1 December 2018

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Persistence of atorvastatin and simvastatin among patients with and without prior cardiovascular diseases: a US managed care study

1 reference

12 December 2020

Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients

1 reference

12 December 2020

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

1 reference

12 December 2020

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

1 reference

12 December 2020

Lipid lowering with PCSK9 inhibitors

1 reference

12 December 2020

Resistance and intolerance to statins

1 reference

12 December 2020

Adverse effects of statins - myths and reality

1 reference

12 December 2020

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial

1 reference

12 December 2020

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

1 reference

12 December 2020

Management of patients with familial hypercholesterolaemia

1 reference

12 December 2020

Efficiency and safety of proprotein convertase subtilisin/kexin 9 monoclonal antibody on hypercholesterolemia: a meta-analysis of 20 randomized controlled trials

1 reference

12 December 2020

Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials

1 reference

12 December 2020

The PCSK9 Inhibitors: A Novel Therapeutic Target Enters Clinical Practice

1 reference

12 December 2020

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

1 reference

12 December 2020

Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors

1 reference

12 December 2020

Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: Payer Approvals and Rejections, and Patient Characteristics for Successful Prescribing

1 reference

12 December 2020

Lipid-lowering therapy with PCSK9-inhibitors in the management of cardiovascular high-risk patients: Effectiveness, therapy adherence and safety in a real world cohort

1 reference

12 December 2020

PCSK9 inhibitors in clinical practice: Expectations and reality

1 reference

12 December 2020

Identifiers

DOI

10.2147/VHRM.S180496

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30573963 AND SRC:MED&resulttype=core&format=json

15 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30573963 AND SRC:MED&resulttype=core&format=json

15 April 2020

PubMed publication ID

30573963

1 reference